MYD88 GENE MUTATION

The MYD88 mutation test is used primarily in the diagnosis and prognosis of certain B-cell lymphomas, especially Waldenström’s macroglobulinemia and chronic lymphocytic leukemia (CLL). The presence of a MYD88 L265P mutation is a key diagnostic marker that influences treatment decisions and helps distinguish between related hematologic malignancies.

This test is recommended when a patient presents with unexplained lymphadenopathy, bone marrow abnormalities, or symptoms related to B-cell malignancies. It’s also used when Waldenström’s macroglobulinemia is suspected, especially if serum IgM is elevated. The test may be performed on bone marrow or peripheral blood samples.

 DNA is extracted from a blood or bone marrow sample and analyzed using polymerase chain reaction (PCR) or next-generation sequencing (NGS) to identify mutations in the MYD88 gene. The procedure is molecular and specialized, usually performed in reference laboratories with results available within a few days to a week.

 A positive MYD88 L265P mutation confirms a strong likelihood of Waldenström’s macroglobulinemia or other specific B-cell lymphomas. The absence of the mutation doesn't completely rule out these diseases but may point toward different subtypes. The result aids in both diagnosis and therapeutic strategy planning.

If the mutation is detected, hematologists will tailor treatment protocols accordingly, which may include targeted therapies. Additional tests such as bone marrow biopsy, immunophenotyping, and serum protein electrophoresis might be ordered to complete the diagnostic picture. Monitoring the disease course will involve both clinical and molecular surveillance.